論文

査読有り
2017年9月

Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology

NEUROLOGY
  • Chiseko Ikenaga
  • ,
  • Akatsuki Kubota
  • ,
  • Masato Kadoya
  • ,
  • Kenichiro Taira
  • ,
  • Naohiro Uchio
  • ,
  • Ayumi Hida
  • ,
  • Meiko Hashimoto Maeda
  • ,
  • Yu Nagashima
  • ,
  • Hiroyuki Ishiura
  • ,
  • Kenichi Kaida
  • ,
  • Jun Goto
  • ,
  • Shoji Tsuji
  • ,
  • Jun Shimizu

89
10
開始ページ
1060
終了ページ
1068
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1212/WNL.0000000000004333
出版者・発行元
LIPPINCOTT WILLIAMS & WILKINS

Objective: To determine the clinical features of myositis patients with the histopathologic finding of CD8-positive T cells invading non-necrotic muscle fibers expressing major histocompatibility complex class 1 (CD8-MHC-1 complex), which is shared by polymyositis (PM) and inclusion body myositis (IBM), in relation to the p62 immunostaining pattern of muscle fibers.
Methods: All 93 myositis patients with CD8-MHC-1 complex who were referred to our hospital from 1993 to 2015 were classified on the basis of the European Neuromuscular Center (ENMC) diagnostic criteria for IBM (Rose, 2013) or PM (Hoogendijk, 2004) and analyzed.
Results: The 93 patients included were 17 patients with PM, 70 patients with IBM, and 6 patients who neither met the criteria for PM nor IBM in terms of muscle weakness distribution (unclassifiable group). For these PM, IBM, and unclassifiable patients, their mean ages at diagnosis were 63, 70, and 64 years; autoimmune disease was present in 7 (41%), 13 (19%), and 4 (67%); hepatitis C virus infection was detected in 0%, 13 (20%), and 2 (33%); and p62 was immunopositive in 0%, 66 (94%), and 2 (33%), respectively. Of the treated patients, 11 of 16 PM patients and 4 of 6 p62-immunonegative patients in the unclassifiable group showed responses to immunotherapy, whereas all 44 patients with IBM and 2 p62-immunopositive patients in the unclassifiable group were unresponsive to immunotherapy.
Conclusions: CD8-MHC-1 complex is present in patients with PM, IBM, or unclassifiable group. The data may serve as an argument for a trial of immunosuppressive treatment in p62-immunonegative patients with unclassifiable myositis.

Web of Science ® 被引用回数 : 7

リンク情報
DOI
https://doi.org/10.1212/WNL.0000000000004333
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000409172500018&DestApp=WOS_CPL